ImmuCell Announces Expansion of Sales and Marketing Team
September 13 2017 - 6:30AM
ImmuCell Corporation (Nasdaq:ICCC), a growing
animal health company that develops, manufactures and markets
scientifically-proven products that improve health and productivity
in the dairy and beef industries, today announced the hiring
of two new Regional Sales and Marketing Managers.
Dale Miller will lead the sales and marketing efforts in the
Northeastern US and Canada. Dale came to ImmuCell with a vast
dairy network and experience in motivating the distribution chain
to multiply our sales efforts.
Rick Choate, residing in Twin Falls, Idaho, will lead the sales
and marketing efforts in the Western US Region. Rick also has
a solid understanding of distribution chain management and hits the
ground running with existing product knowledge, as he sold our lead
product, First Defense®, during a prior position
within our distribution chain.
When an open position in the Midwestern US Region is filled,
ImmuCell’s team will consist of eight members, representing a net
increase from seven previously.
“We consider ourselves the ‘Davids’ amongst ‘Goliaths’ within
the animal pharmaceutical world,” commented Bobbi Jo Brockmann,
ImmuCell’s vice president of sales and marketing. “We exhibit
a farm-kid like work ethic and approachability with a real desire
to help improve the health and profitability of calf enterprises
for the dairy and beef industries. Our creativity, tenacity
and laser focus is what sets us apart from the rest.”
During the fourth quarter of 2017, the Company expects to
achieve regulatory approval of First
Defense® Tri-Shield™, a new
formulation of its bovine antibodies that combines the existing
bivalent claims (against E. coli and coronavirus) of the
First Defense® capsule with a new rotavirus claim
in a gel tube delivery format. The Company is working to also
achieve regulatory approval of First
Defense® Dual-Force™, its
bivalent gel tube formulation that is currently sold without
disease claims as First Defense Technology®.
“Because Miller and Choate come to us with such experience, we
expect them to have an immediate impact on our efforts to grow
sales of the First Defense®
product line,” commented Michael F. Brigham, ImmuCell’s president
and CEO. “We ask our sales team to cover large territories,
and these extra resources will better prepare us for the
anticipated new product launches.”
About ImmuCell: ImmuCell Corporation's
(Nasdaq:ICCC) purpose is to create scientifically-proven and
practical products that improve animal health and productivity in
the dairy and beef industries. ImmuCell has developed products
that provide significant, immediate immunity to newborn dairy and
beef livestock. The Company is developing a novel treatment for
mastitis, the most significant cause of economic loss to the dairy
industry. Press releases and other information about the Company
are available at: (http://www.immucell.com).
Contacts:
Michael F. Brigham, President and CEOImmuCell Corporation(207)
878-2770
Joe Diaz, Robert Blum and Joe DorameLytham Partners, LLC(602)
889-9700iccc@lythampartners.com
Safe Harbor Statement:
This Press Release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to:
projections of future financial performance; the scope and timing
of ongoing and future product development work and
commercialization of our products; future costs of product
development efforts; the estimated prevalence rate of subclinical
mastitis; future market share of and revenue generated by current
products and products still in development; future sources of
financial support for our product development, manufacturing and
marketing efforts; the future adequacy of our own manufacturing
facilities or those of third parties with which we have contractual
relationships to meet demand for our products on a timely basis;
the future adequacy of our working capital and the availability and
cost of third party financing; timing and future costs of a
facility to produce the Drug Substance (our active pharmaceutical
ingredient, Nisin); the timing and outcome of pending or
anticipated applications for regulatory approvals; future
regulatory requirements relating to our products; future expense
ratios and margins; future compliance with bank debt covenants;
costs associated with sustaining compliance with cGMP regulations
in our current operations and attaining such compliance for the
facility to produce the Drug Substance; factors that may affect the
dairy and beef industries and future demand for our products; our
effectiveness in competing against competitors within both our
existing and our anticipated product markets; the
cost-effectiveness of additional sales and marketing expenditures
and resources; the accuracy of our understanding of our
distributors’ ordering patterns; anticipated changes in our
manufacturing capabilities and efficiencies; anticipated
competitive and market conditions; and any other statements that
are not historical facts. Forward-looking statements can be
identified by the use of words such as “expects”, “may”,
“anticipates”, “aims”, “intends”, “would”, “could”, “should”,
“will”, “plans”, “believes”, “estimates”, “targets”, “projects”,
“forecasts” and similar words and expressions. In addition, there
can be no assurance that future developments affecting us will be
those that we anticipate. Such statements involve risks and
uncertainties, including, but not limited to, those risks and
uncertainties relating to difficulties or delays in development,
testing, regulatory approval, production and marketing of our
products, competition within our anticipated product markets,
customer acceptance of our new and existing products, alignment
between our manufacturing resources and product demand, the
uncertainties associated with product development and Drug
Substance manufacturing, actual as compared to expected or
estimated costs of expanding our manufacturing facilities, our
potential reliance upon third parties for financial support,
products and services, changes in laws and regulations, decision
making by regulatory authorities, possible dilutive impacts on
existing stockholders from any equity financing transactions in
which we may engage, currency values and fluctuations and other
risks detailed from time to time in filings we make with the
Securities and Exchange Commission, including our Quarterly Reports
on Form 10-Q, our Annual Reports on Form 10-K and our Current
Reports on Form 8-K. Such statements are based on our current
expectations, but actual results may differ materially due to
various factors, including the risk factors discussed above.
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2023 to Apr 2024